Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT)
Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million by the Cancer Prevention and Research Institute of Texas (CPRIT).
The grant will support the Phase IA/B clinical trials of the company’s first-in-class anti-VISTA therapeutic antibody for the treatment of VISTA mediated suppression of anti-tumor immunity in solid tumors and lymphomas that are unresponsive to existing therapies. Hummingbird Bioscience is a systems-biology enabled biotech company focused on the discovery and development of novel cancer therapeutics.
The CPRIT review for this grant included an in-depth evaluation of HMBD-002, an antibody that uniquely neutralizes VISTA function, by a panel of scientific, medical, and industry experts. The evaluation included rigorous review of the pre-clinical data, as well as regulatory, research and development, and intellectual property due diligence.
The grant will support the Phase IA/B clinical study and preparatory steps including GMP manufacturing and Investigational New Drug (IND) submission for the HMBD-002 program. The grant will also support the relocation of the company’s U.S. headquarters to Texas. Clinical trials for HMBD-002 are anticipated to begin in 2020. Hummingbird Bioscience was the only successful application of its type for this grant cycle.
“We are delighted to be awarded this highly-selective grant from CPRIT and to start building our operations in Texas,” said Piers Ingram, Ph.D., CEO of Hummingbird Bioscience. “Our company applies systems biology approaches to generate uniquely differentiated therapeutic antibodies. We are thrilled CPRIT’s panel of experts agrees that developing this anti-VISTA immuno-oncology program has the potential to significantly benefit patients.”
About Hummingbird Bioscience
Hummingbird Bioscience is an innovative therapeutics development company with a proprietary rational antibody discovery platform and deep experience in applying integrative genomics and proteomics. Hummingbird develops precision therapeutic antibodies to clinical proof-of-concept for patients with the highest unmet need. The company has a pipeline of first or best-in-class drug candidates. Within its pipeline, HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody) are anticipated to start clinical trials in 2020. The company has locations in South San Francisco, CA and Singapore. For more information on Hummingbird Bioscience visit: http://hummingbirdbioscience.com
McDougall Communications on behalf of Hummingbird Bioscience Contact: Elizabeth Harness, firstname.lastname@example.org, Tel: +1 (585) 435 -7379